多巴酚丁胺负荷超声心动图缺血预测PCI疗效:ORBITA-2试验结果
该研究为ORBITA-2试验的DSE分层二次分析,纳入262例稳定型心绞痛且单支或多支CAD患者,在停用抗心绞痛药物后随机前进行DSE。结果显示,DSE负荷超声心动图评分越高,PCI相比安慰剂对心绞痛症状评分、每日心绞痛发作次数及生活质量改善越显著。
要点
- DSE评估的缺血负荷越高,PCI安慰剂对照的症状改善越明显。
- DSE评分可预测PCI后每日心绞痛发作减少,且不受症状特征影响。
- DSE或可用于筛选从PCI获益更大的稳定型CAD患者。
核心结论
- 在单支或多支稳定型CAD且少用或不用抗心绞痛药物的患者中,DSE检测的缺血程度可预测PCI的安慰剂对照疗效,基线缺血负担越大,PCI后症状和生活质量改善越明显。
研究设计与样本
- ORBITA-2试验的DSE分层二次分析,纳入有心绞痛、单支或多支CAD且存在缺血的患者,停用抗心绞痛药物后随机前完成ORBITA-app、问卷、DSE和运动平板试验。
- 随机前DSE数据可用的患者共262例,中位年龄65.5岁(Q1-Q3:59-71岁),男性208例(79.4%)。
- 应激超声心动图评分按左室各节段在峰值负荷时计算,正常、运动减弱、无运动、矛盾运动和无室壁瘤节段分别计0至4分。
- 采用贝叶斯比例优势模型分析。
主要发现
- 基线时应激超声心动图评分中位数在PCI组(n=133)为1.42,安慰剂组(n=129)为1.00,总体中位数为1.25(Q1-Q3:0.33-2.92)。
- 较高的应激超声心动图评分与PCI后心绞痛症状评分更大的安慰剂对照改善强相关(OR:1.23;95% CrI:1.13-1.35;Pr(interaction) > 99.9%)。
- 较高评分也预测每日心绞痛发作显著减少(OR:1.36;95% CrI:1.24-1.49;Pr(interaction) > 99.9%)。
- 较高评分还预测西雅图心绞痛问卷心绞痛频率评分改善(8.22;95% CrI:0.96-15.50;Pr(interaction) = 98.7%)和生活质量评分改善(8.95;95% CrI:2.05-16.00;Pr(interaction) = 99.3%)。
- 应激超声心动图评分与每日心绞痛发作减少的关系不受症状特征影响,保持一致。
临床怎么用
- 对稳定型CAD患者,可用DSE评估缺血负荷来辅助预测PCI的症状获益,缺血负担越重者PCI后症状和生活质量改善可能越大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ORBITA-2 (The Placebo-Controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina) found that percutaneous coronary intervention (PCI) relieved angina in patients with single-vessel and multivessel stable coronary artery disease (CAD) on little or no antianginal medication. Whereas symptom characteristics and invasive physiological assessments can predict PCI efficacy, the role of noninvasive imaging with dobutamine stress echocardiography (DSE) remains unclear. OBJECTIVES: This DSE-stratified secondary analysis of ORBITA-2 investigates the relationship between ischemia, assessed by DSE, and the placebo-controlled efficacy of PCI. METHODS: Participants with angina, single-vessel or multivessel CAD, and ischemia were enrolled. Following discontinuation of antianginal medications, patients were evaluated prerandomization using the ORBITA-app, questionnaires, DSE, and exercise treadmill testing. Stress echocardiography scores were calculated for each left ventricular segment at peak stress, with normal, hypokinetic, akinetic, dyskinetic, and aneurysmal segments scoring 0 to 4, respectively. Bayesian proportional odds modeling was used. RESULTS: Prerandomization DSE data were available for 262 patients. The median age was 65.5 years (Q1-Q3: 59-71 years), and 208 (79.4%) were male. At baseline, the median stress echocardiography score was 1.42 in the PCI group (n = 133) and 1.00 in the placebo group (n = 129), with an overall median score of 1.25 (Q1-Q3: 0.33-2.92). Higher stress echocardiography scores were strongly associated with greater placebo-controlled improvements in angina symptom score following PCI (OR: 1.23; 95% credible interval [CrI]: 1.13-1.35; Pr(interaction) > 99.9%). Higher scores also predicted significant reduction in daily angina episodes (OR: 1.36; 95% CrI: 1.24-1.49; Pr(interaction) > 99.9%), as well as improvement in the Seattle Angina Questionnaire angina frequency score (8.22; 95% CrI: 0.96-15.50; Pr(interaction) = 98.7%), and Seattle Angina Questionnaire quality of life score (8.95; 95% CrI: 2.05-16.00; Pr(interaction) = 99.3%). The relationship between stress echocardiography score and reduction in daily angina episodes remained consistent, irrespective of symptom characteristics. CONCLUSIONS: In patients with single- and multivessel stable CAD on little or no antianginal medication, the placebo-controlled efficacy of PCI was predicted by the degree of ischemia detected on DSE. The greater the burden of baseline ischemia, the greater the improvement in symptoms and quality of life with PCI.
引用
- Ahmed-Jushuf F, Foley MJ, Rajkumar CA, et al. Ischemia on Dobutamine Stress Echocardiography Predicts Efficacy of PCI: Results From the ORBITA-2 Trial. J Am Coll Cardiol. 2025. PMID: 40335250. doi:10.1016/j.jacc.2025.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。